Kurzfassung

Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation after reduced intensity conditioning with fludarabine and treosulfan